Ascendis Pharma A/S announced positive Week 26 interim analysis results from its Phase 2 COACH Trial, which is the first clinical trial to evaluate combination treatment with once-weekly investigational TransCon CNP and once-weekly TransCon hGH in children with achondroplasia. The results demonstrated that TransCon hGH boosted the treatment benefits of TransCon CNP.
For the TransCon CNP treatment-naïve cohort, combination treatment resulted in a mean annualized growth velocity (AGV) of 9.14 cm/year, with an improvement in mean ACH height Z-score of +0.53 over 26 weeks. The TransCon CNP-treated cohort also showed a mean AGV of 8.25 cm/year and an improvement in mean ACH height Z-score of +0.44.
The combination therapy demonstrated accelerated improvement in body proportionality at Week 26, aligning with the increase in linear growth. The safety and tolerability data were consistent with those observed for TransCon hGH and TransCon CNP monotherapies, with generally mild treatment-emergent adverse events. Ascendis plans to initiate a Phase 3 trial for this combination in Q4 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.